COVID-19 Vaccination in Adolescents: Side Effects and Symptomatic Reinfections

被引:0
作者
Mazaheri, Maryam [1 ]
Moazen, Javad [2 ]
Rezaei, Zahed [3 ]
Aghababaeian, Hamidreza [4 ,5 ]
Mohebbi, Leila [6 ]
Eghtedari, Mohammad Amin [7 ]
Nikjoo, Mohammad [7 ]
Shoush, Ali [7 ]
Hedayat, Zahra [8 ]
机构
[1] Dezful Univ Med Sci DUMS, Sch Med, Dept Social Med & Family, Dezful, Iran
[2] Dezful Univ Med Sci DUMS, Infect & Trop Dis Res Ctr, Sch Med, Dezful, Iran
[3] Asadabad Sch Med Sci, Asadabad 6541743897, Iran
[4] Dezful Univ Med Sci DUMS, Dept Med Emergencies, Dezful, Iran
[5] Dezful Univ Med Sci DUMS, Ctr Climate Change & Hlth Res CCCHR, Dezful, Iran
[6] Dezful Univ Med Sci DUMS, Dept Hlth, Dezful, Iran
[7] Dezful Univ Med Sci DUMS, Sch Med, Dezful, Iran
[8] Ahvaz Jundishapur Univ Med Sci AJUMS, Student Res Comm, Ahvaz, Iran
来源
ARCHIVES OF CLINICAL INFECTIOUS DISEASES | 2023年 / 18卷 / 06期
关键词
PastoCovac Vaccine; Sinopharm Vaccine; SARS-COV-2; Reinfection; Side Effects; Symptomatic Reinfections;
D O I
10.5812/archcid-142060
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Although the COVID-19 pandemic is over, the disease remains a public health threat. Contracting and transmitting SARS-COV-2 among individuals under 18 is significant. Objectives: This study aims to identify potential side effects and symptomatic reinfections among 12 -18 -year -olds after receiving COVID-19 vaccines. Methods: In this longitudinal study conducted in 2021- 2022 in Dezful, Iran, 1,000 vaccinated individuals were followed up for 6 months. Side effects and symptomatic reinfections of the first and second doses of PastoCovac and Sinopharm vaccines and a history of prior SARS-COV-2 infection were recorded. Results: Only 7.6% received the PastoCovac vaccine, while 92.4% received the Sinopharm vaccine. The most common side effect for both vaccines was local pain at the injection site, while the least common was skin rash. Side effects were 1.9 times more prevalent with the PastoCovac vaccination. Women had a 2.3 times higher chance of experiencing side effects after the first dose and a 1.9 times higher chance after the second dose compared to men. Over the 6 -month follow-up period, 11.6% and 14.3% of individuals experienced re -infection after the first and second vaccine doses, respectively. It seems with the passage of time and the decrease in the level of immunity, the possibility of re -infection increases. Conclusions: Both vaccines were considered safe for 12 -18 -year -olds. However, receiving two doses does not guarantee protection against reinfection.
引用
收藏
页数:10
相关论文
共 44 条
  • [1] Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines
    Abu-Hammad, Osama
    Alduraidi, Hamza
    Abu-Hammad, Shaden
    Alnazzawi, Ahmed
    Babkair, Hamzah
    Abu-Hammad, Abdalla
    Nourwali, Ibrahim
    Qasem, Farah
    Dar-Odeh, Najla
    [J]. VACCINES, 2021, 9 (06)
  • [2] Al-Jahdhami Issa, 2022, Oman Med J, V37, pe343, DOI 10.5001/omj.2022.52
  • [3] Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
    Ali, Kashif
    Berman, Gary
    Zhou, Honghong
    Deng, Weiping
    Faughnan, Veronica
    Coronado-Voges, Maria
    Ding, Baoyu
    Dooley, Jacqueline
    Girard, Bethany
    Hillebrand, William
    Pajon, Rolando
    Miller, Jacqueline M.
    Leav, Brett
    McPhee, Roderick
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24) : 2241 - 2251
  • [4] Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
    Anderson, E. J.
    Rouphael, N. G.
    Widge, A. T.
    Jackson, L. A.
    Roberts, P. C.
    Makhene, M.
    Chappell, J. D.
    Denison, M. R.
    Stevens, L. J.
    Pruijssers, A. J.
    McDermott, A. B.
    Flach, B.
    Lin, B. C.
    Doria-Rose, N. A.
    O'Dell, S.
    Schmidt, S. D.
    Corbett, K. S.
    Swanson, P. A., II
    Padilla, M.
    Neuzil, K. M.
    Bennett, H.
    Leav, B.
    Makowski, M.
    Albert, J.
    Cross, K.
    Edara, V. V.
    Floyd, K.
    Suthar, M. S.
    Martinez, D. R.
    Baric, R.
    Buchanan, W.
    Luke, C. J.
    Phadke, V. K.
    Rostad, C. A.
    Ledgerwood, J. E.
    Graham, B. S.
    Beigel, J. H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) : 2427 - 2438
  • [5] Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]
  • [6] Adverse effects following COVID-19 vaccination in Iran
    Babaee, Ebrahim
    Amirkafi, Ali
    Tehrani-Banihashemi, Arash
    SoleimanvandiAzar, Neda
    Eshrati, Babak
    Rampisheh, Zahra
    Asadi-Aliabadi, Mehran
    Nojomi, Marzieh
    [J]. BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [7] Berkeley LJ, 2021, FDA Permits Use of the Pfizer-BioNTech COVID Vaccine in Kids Ages 12 to 15 2021
  • [8] A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca
    Boshra, Marian S.
    Hussein, Raghda R. S.
    Mohsen, Marwa
    Elberry, Ahmed A.
    Altyar, Ahmed E.
    Tammam, Mahmoud
    Sarhan, Rania M.
    [J]. VACCINES, 2022, 10 (02)
  • [9] Centers for Disease Control and Prevention, 2021, COVID-19 Vaccines for Children and Teens
  • [10] Chemaitelly H, 2022, LANCET, V399, P771, DOI 10.1016/S0140-6736(22)00277-X